All In Biotech

Drug Trial Radar · NCT02145468

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.

Last checked: Nov 20, 2026Latest source record: Jun 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,503 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,503

Actual

Start

Jun 3, 2014

Primary completion

Dec 14, 2015

Study completion Dec 14, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
The TIMI Study Group
First posted
May 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack. There is a growing understanding that the inflammatory response to ACS is integral to the subsequent evolution of plaque instability. Losmapimod inhibits p38 mitogen activated protein kinase (MAPK), an enzyme which may play a central role in inflammation in the setting of heart attack. Inhibition of p38 MAPK may stabilize atherosclerotic plaques, reduce the risk of subsequent plaque rupture, indirectly improve vascular function and prevent subsequent thrombosis, and thus reduce infarct size and the risk of subsequent cardiac events. This study will test whether losmapimod can safely reduce the risk of a subsequent cardiovascular event (such as death, heart attack, or near heart attack requiring urgent treatment ) when started immediately after ACS (specifically, heart attack). Patients who present with heart attack and qualify for the study will be randomly assigned to receive 3 months treatment with either losmapimod twice daily or placebo, which will be administered in addition to the usual standard of care therapies for heart attack. Following the in-hospital period, subjects will return for outpatient visits at 4 and 12 weeks, as well as a follow up visit at 24 weeks.

Conditions

  • Acute Coronary Syndrome

Interventions

  • Losmapimod 7.5 mg twice dailyDrug

    Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.

  • Placebo twice dailyDrug

    Subjects will receive placebo as film-coated, round, plain faced tablets.

  • Standard therapyDrug

    Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12Time frame: Up to 12 weeks

Locations

341 sites in 34 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Cottonwood, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Mission Viejo, California

  • GSK Investigational Site

    Monterey, California

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Littleton, Colorado

  • GSK Investigational Site

    Daytona Beach, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Jacksonville Beach, Florida

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Tallahassee, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Vero Beach, Florida

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Rome, Georgia

  • GSK Investigational Site

    Coeur d'Alene, Idaho

  • GSK Investigational Site

    Aurora, Illinois

  • GSK Investigational Site

    Elmhurst, Illinois

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Muncie, Indiana

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    West Des Moines, Iowa

  • GSK Investigational Site

    Alexandria, Louisiana

  • GSK Investigational Site

    Baton Rouge, Louisiana

  • GSK Investigational Site

    Slidell, Louisiana

  • GSK Investigational Site

    Zachary, Louisiana

  • GSK Investigational Site

    Auburn, Maine

  • GSK Investigational Site

    Boston, Massachusetts

Showing 40 of 341 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.